Administration of insulin-like growth factor-I (IGF-I) peptides for three days stimulates proliferation of the small intestinal epithelium in rats.

Steeb CB, Trahair JF, Read LC

Gut1 Nov 1995Cited by 40 (Europe PMC)

PMID8549937PMCIDPMC1382866DOI10.1136/gut.37.5.630PepBankPUB-08549937

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In female rats, 3 days of LR3IGF-I infusion, but not IGF-I, increased body weight compared with controls.
In plain wordsIn rats, LR3IGF-I raised body weight compared with controls. IGF-I did not.
Peptide
IGF-1 LR3
Outcome
IncreaseBody weight
Study
ratn: not reported in source
Female rats, 110 g
Comparator
Vehicle-treated or untreated control rats
Outcome group
Body weight · Metabolic and weight
Studied dose
2.5 mg/kg/day · 3 daysAs given in this study (rat).
Source sentences
Summary
LR3IGF-I but not IGF-I increased body weight and wet tissue weight of the small and large intestine (+20%), compared with controls.
1 context sentence(design, population, supporting numbers)
Summary · context
Female rats (110 g, five-six/group) were infused for three days with 2.5 mg/kg/day of either IGF-I or LR3IGF-I and compared with vehicle treated or untreated control rats.
Report a problemFND-0854993701
02AnimalAnimal study (in vivo)Efficacy outcome
In female rats, LR3IGF-I, but not IGF-I, increased the wet tissue weight of the small intestine by 20% compared with controls.
In plain wordsIn rats, LR3IGF-I increased small intestine weight compared with controls. IGF-I did not.
Peptide
IGF-1 LR3
Outcome
IncreaseWet weight of small intestine
Study
ratn: not reported in source
Female rats, 110 g
Comparator
Vehicle-treated or untreated control rats
Outcome group
Intestinal growth and absorption · Gastrointestinal
Studied dose
2.5 mg/kg/day · 3 daysAs given in this study (rat).
Measurements
Wet tissue weight change
20%
small intestine
Source sentences
Summary
LR3IGF-I but not IGF-I increased body weight and wet tissue weight of the small and large intestine (+20%), compared with controls.
1 context sentence(design, population, supporting numbers)
Summary · context
Female rats (110 g, five-six/group) were infused for three days with 2.5 mg/kg/day of either IGF-I or LR3IGF-I and compared with vehicle treated or untreated control rats.
Report a problemFND-0854993702
03AnimalAnimal study (in vivo)Efficacy outcome
In female rats, LR3IGF-I, but not IGF-I, increased the wet tissue weight of the large intestine by 20% compared with controls.
In plain wordsIn rats, LR3IGF-I increased large intestine weight compared with controls. IGF-I did not.
Peptide
IGF-1 LR3
Outcome
IncreaseWet weight of large intestine
Study
ratn: not reported in source
Female rats, 110 g
Comparator
Vehicle-treated or untreated control rats
Outcome group
Intestinal growth and absorption · Gastrointestinal
Studied dose
2.5 mg/kg/day · 3 daysAs given in this study (rat).
Measurements
Wet tissue weight change
20%
large intestine
Source sentences
Summary
LR3IGF-I but not IGF-I increased body weight and wet tissue weight of the small and large intestine (+20%), compared with controls.
1 context sentence(design, population, supporting numbers)
Summary · context
Female rats (110 g, five-six/group) were infused for three days with 2.5 mg/kg/day of either IGF-I or LR3IGF-I and compared with vehicle treated or untreated control rats.
Report a problemFND-0854993703
04AnimalAnimal study (in vivo)Efficacy outcome
In female rats, LR3IGF-I increased duodenal crypt length by 13%.
In plain wordsIn rats, LR3IGF-I lengthened the crypts of the first part of the small intestine.
Peptide
IGF-1 LR3
Outcome
IncreaseDuodenal crypt length
Study
ratn: not reported in source
Female rats, 110 g
Comparator
Vehicle-treated or untreated control rats
Outcome group
Intestinal growth and absorption · Gastrointestinal
Studied dose
2.5 mg/kg/day · 3 daysAs given in this study (rat).
Measurements
Duodenal crypt length increase
13%
LR3IGF-I treated rats
Source sentences
Summary
In LR3IGF-I treated animals, duodenal and ileal crypts length were increased by 13 and 22%, respectively, associated with an increase in crypt cell number.
1 context sentence(design, population, supporting numbers)
Summary · context
Female rats (110 g, five-six/group) were infused for three days with 2.5 mg/kg/day of either IGF-I or LR3IGF-I and compared with vehicle treated or untreated control rats.
Report a problemFND-0854993704
05AnimalAnimal study (in vivo)Efficacy outcome
In female rats, LR3IGF-I increased ileal crypt length by 22%.
In plain wordsIn rats, LR3IGF-I lengthened the crypts of the last part of the small intestine.
Peptide
IGF-1 LR3
Outcome
IncreaseIleal crypt length
Study
ratn: not reported in source
Female rats, 110 g
Comparator
Vehicle-treated or untreated control rats
Outcome group
Intestinal growth and absorption · Gastrointestinal
Studied dose
2.5 mg/kg/day · 3 daysAs given in this study (rat).
Measurements
Ileal crypt length increase
22%
LR3IGF-I treated rats
Source sentences
Summary
In LR3IGF-I treated animals, duodenal and ileal crypts length were increased by 13 and 22%, respectively, associated with an increase in crypt cell number.
1 context sentence(design, population, supporting numbers)
Summary · context
Female rats (110 g, five-six/group) were infused for three days with 2.5 mg/kg/day of either IGF-I or LR3IGF-I and compared with vehicle treated or untreated control rats.
Report a problemFND-0854993705
06AnimalAnimal study (in vivo)Efficacy outcome
In female rats, longer duodenal and ileal crypts after LR3IGF-I were associated with an increase in crypt cell number.
In plain wordsIn rats, LR3IGF-I treatment came with more cells in the intestinal crypts.
Peptide
IGF-1 LR3
Outcome
IncreaseCrypt cell number
Study
ratn: not reported in source
Female rats, 110 g
Comparator
Vehicle-treated or untreated control rats
Outcome group
Intestinal growth and absorption · Gastrointestinal
Studied dose
2.5 mg/kg/day · 3 daysAs given in this study (rat).
Source sentences
Summary
In LR3IGF-I treated animals, duodenal and ileal crypts length were increased by 13 and 22%, respectively, associated with an increase in crypt cell number.
1 context sentence(design, population, supporting numbers)
Summary · context
Female rats (110 g, five-six/group) were infused for three days with 2.5 mg/kg/day of either IGF-I or LR3IGF-I and compared with vehicle treated or untreated control rats.
Report a problemFND-0854993706
07AnimalAnimal study (in vivo)Efficacy outcome
In female rats, LR3IGF-I significantly increased the thymidine labelling index in the duodenum, by up to 14%.
In plain wordsIn rats, LR3IGF-I increased cell division in the duodenum.
Peptide
IGF-1 LR3
Outcome
IncreaseThymidine labelling index, duodenum
Study
ratn: not reported in source
Female rats, 110 g
Comparator
Vehicle-treated or untreated control rats
Outcome group
Intestinal growth and absorption · Gastrointestinal
Studied dose
2.5 mg/kg/day · 3 daysAs given in this study (rat).
Measurements
Thymidine labelling index increase
≤ 14%
duodenum
Source sentences
Summary
Tritiated thymidine labelling indices were significantly increased after administration of either IGF-I or LR3IGF-I (up to 14%) in both the duodenum and ileum.
1 context sentence(design, population, supporting numbers)
Summary · context
Female rats (110 g, five-six/group) were infused for three days with 2.5 mg/kg/day of either IGF-I or LR3IGF-I and compared with vehicle treated or untreated control rats.
Report a problemFND-0854993707
08AnimalAnimal study (in vivo)Efficacy outcome
In female rats, LR3IGF-I significantly increased the thymidine labelling index in the ileum, by up to 14%.
In plain wordsIn rats, LR3IGF-I increased cell division in the ileum.
Peptide
IGF-1 LR3
Outcome
IncreaseThymidine labelling index, ileum
Study
ratn: not reported in source
Female rats, 110 g
Comparator
Vehicle-treated or untreated control rats
Outcome group
Intestinal growth and absorption · Gastrointestinal
Studied dose
2.5 mg/kg/day · 3 daysAs given in this study (rat).
Measurements
Thymidine labelling index increase
≤ 14%
ileum
Source sentences
Summary
Tritiated thymidine labelling indices were significantly increased after administration of either IGF-I or LR3IGF-I (up to 14%) in both the duodenum and ileum.
1 context sentence(design, population, supporting numbers)
Summary · context
Female rats (110 g, five-six/group) were infused for three days with 2.5 mg/kg/day of either IGF-I or LR3IGF-I and compared with vehicle treated or untreated control rats.
Report a problemFND-0854993708
09AnimalAnimal study (in vivo)Efficacy outcome
In female rats, the number of thymidine-labelled colon cells rose non-significantly.
In plain wordsIn rats, cell division in the colon was low and did not rise significantly.
Peptide
IGF-1 LR3
Outcome
No significant changeThymidine labelling in colon
Study
ratn: not reported in source
Female rats, 110 g
Comparator
Vehicle-treated or untreated control rats
Outcome group
Intestinal growth and absorption · Gastrointestinal
Studied dose
2.5 mg/kg/day · 3 daysAs given in this study (rat).
Source sentences
Summary
In the colon, the thymidine labelling index was low, however, a non-significant increase in the number of cells labelled with thymidine was seen.
1 context sentence(design, population, supporting numbers)
Summary · context
Female rats (110 g, five-six/group) were infused for three days with 2.5 mg/kg/day of either IGF-I or LR3IGF-I and compared with vehicle treated or untreated control rats.
Report a problemFND-0854993709

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.